AstraZeneca Outlines Branded Generics Strategy at Emerging Markets Event
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca plans to broaden its presence across a wide range of developing markets, including small and mid-sized ones, not only to maximize growth but also to smooth out variations in growth rates across countries and regions, top company executives said in a detailed presentation to analysts on March 16
You may also be interested in...
Asia Spotlight: AstraZeneca Shakeup Of China Business Unit Steers Focus Away From Generics To Innovative Drugs
AstraZeneca will dissolve its Broad Market business unit in China by merging it with primary care and move away from attracting business for branded generics in tier-3 rural markets, putting flesh on new CEO Pascal Soriot’s plan to focus on innovation.
AstraZeneca Shakeup Of China Business Unit Steers Focus Away From Generics To Innovative Drugs
AstraZeneca will dissolve its Broad Market business unit in China by merging it with primary care and move away from attracting business for branded generics in tier-3 rural markets, putting flesh on new CEO Pascal Soriot’s plan to focus on innovation.
Soriot Effect Sees AstraZeneca Selectively Scale Back Branded Generics In Emerging Markets
Leadership change is forcing the Anglo-Swedish drug giant to review its priorities in the branded generics business. AstraZeneca will invest selectively in countries where it has built a high base and shows ability to post robust growth.